483 episodes
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
09/29/2026 | 7 mins.CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
09/28/2026 | 9 mins.Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
09/28/2026 | 13 mins.CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028.Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study
09/21/2026 | 9 mins.Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs
09/16/2026 | 14 mins.She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical.
Sidenote by AsapSCIENCEComedy, Life Sciences, Science
UnexplainableLife Sciences, Science
Health Optimization Medicine PodcastAlternative Health, Health & Wellness, Life Sciences, Science
Science FridayEarth Sciences, Life Sciences, Natural Sciences, Science
Short WaveDaily News, Life Sciences, News, Science
The Quanta PodcastLife Sciences, Science
Science of Perception BoxHealth & Wellness, Life Sciences, Mental Health, Science
Stuff To Blow Your MindLife Sciences, Science
Speaking of PsychologyHealth & Wellness, Life Sciences, Mental Health, Science
Listen to BiotechTV - News, Sidenote by AsapSCIENCE and many other podcasts from around the world with the radio.net app
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
BiotechTV - News
download the app,
start listening.
USA